PainReform Ltd (PRFX)

[Muhbruh]

$PRFX low float nanocap bio with upcoming cat
- 65k borrows
- has 1.86m float & 1.89m OS with 10m AS cap
- last offer @ $3.83

catalyst;
- Expected closing of the transaction by the end of July 2025.
PainReform Ltd. has entered into a Preferred Stock Purchase Agreement to acquire 51% of LayerBio's share capital. The transaction is expected to close by the end of July 2025.

> PainReform Ltd. has signed a strategic investment agreement with LayerBio Inc. to enhance its non-opiate pain management pipeline by introducing a new drug delivery platform targeting cataract surgeries. LayerBio's OcuRing™-K is designed to provide a sustained-release treatment for pain and inflammation, potentially replacing traditional eye drops. The investment aims to fund a Phase II clinical trial for OcuRing-K, with PainReform acquiring a majority equity stake in LayerBio.
> Key upcoming dates, timelines or potential catalysts:
>
> The transaction is expected to close by the end of July 2025, subject to customary closing conditions.